SALT Fund

SALT is a venture capital firm based in New York City, founded in 2009. The firm focuses on making investments at various stages, including seed, early, and late-stage funding, to support innovative companies and drive growth. As an investment fund, SALT aims to identify and nurture promising business opportunities across diverse sectors, leveraging its expertise to enhance the success of its portfolio companies.

Alexander Klokus

Managing Partner

AJ Scaramucci

Managing Partner

26 past transactions

Manifest

Pre Seed Round in 2025
Manifest is the simplest way for investors worldwide to access institutional-grade U.S. real estate through onchain ownership.

Shuttle Labs

Seed Round in 2024
Lore is developing the network and consumer tooling to onboard the next 1B users.

Fission Labs

Pre Seed Round in 2024
Fission Labs democratize access to VC investing by creating a global, liquid, on-chain marketplace.

OpenGradient

Seed Round in 2024
OpenGradient is a decentralized AI platform that hosts open-source models, enables secure inference, and supports deployment of AI applications. It provides native model hosting, permissionless composability, and secure execution to accelerate open-source AI while improving verifiability and enabling censorship-resistant model access. The platform relies on a heterogeneous AI compute architecture and a proprietary library to power secure AI workflows, including inference, agentic reasoning, and analysis. A web portal and SDK let developers leverage the AI stack without blockchain complexity, helping them build secure, auditable workflows. OpenGradient aims to democratize model ownership and promote transparency in AI by enabling scalable, verifiable computing across open-source models.

OpenGradient

Seed Round in 2024
OpenGradient is a decentralized AI platform that hosts open-source models, enables secure inference, and supports deployment of AI applications. It provides native model hosting, permissionless composability, and secure execution to accelerate open-source AI while improving verifiability and enabling censorship-resistant model access. The platform relies on a heterogeneous AI compute architecture and a proprietary library to power secure AI workflows, including inference, agentic reasoning, and analysis. A web portal and SDK let developers leverage the AI stack without blockchain complexity, helping them build secure, auditable workflows. OpenGradient aims to democratize model ownership and promote transparency in AI by enabling scalable, verifiable computing across open-source models.

Hemi Labs

Seed Round in 2024
Hemi Labs is a developer of a modular blockchain network that enhances the functionalities of Bitcoin and Ethereum by integrating them into a unified supernetwork. This innovative approach focuses on improving blockchain interoperability and scaling, allowing for seamless cross-chain portability and programmability. Hemi's network offers advanced security features, known as "superfinality," which surpass the security levels of Bitcoin. Co-founded by Jeff Garzik, a former Bitcoin core developer, and Max Sanchez, the inventor of the Proof-of-Proof consensus protocol, Hemi Labs is supported by a team of experienced blockchain engineers and strategic partners. The company's mission is to redefine the interaction between leading blockchain networks, enabling users to move their assets effortlessly while accessing new capabilities.

Gameto

Series B in 2024
Gameto is a biotechnology company focused on advancing female reproductive health through innovative therapies. Recognizing the significant lack of treatment options in this underserved area, Gameto employs cutting-edge scientific techniques to develop solutions that enhance the quality of life for women. The company utilizes cellular engineering to create a platform that produces engineered ovarian and endometrial cell lines capable of mimicking the functions of natural cells, including hormone production and response. This platform underpins a portfolio of cellular therapeutics aimed at addressing various female reproductive diseases. Gameto's first initiative, Fertilo, targets improvements in in vitro fertilization (IVF) and egg freezing processes, striving to make them shorter, safer, and more effective. Additionally, the company is developing Deovo, an organoid model of the female reproductive system, and Ameno, a cell-based therapy designed to mitigate health issues related to primary ovarian insufficiency and menopause. Through these efforts, Gameto aims to transform the landscape of female reproductive health care.

Hinkal Protocol

Seed Round in 2024
Hinkal is a self-service dApp and SDK that allows liquid funds, institutions, whales, and consumers to run their strategies privately on their favorite dApps.

Crypto Valley Exchange

Seed Round in 2024
CVEX is a decentralized exchange that provides cryptocurrency holders with futures and options trading, using specific bid-offer dynamics to undercut other trading platforms.

Blueprint Finance

Venture Round in 2024
Blueprint Finance is a technology company that specializes in developing protocols and infrastructure to enhance on-chain finance. It creates decentralized software designed to protect future traders from significant market events, aiming to foster the safety and growth of the global crypto market. The company's platform, an app chain tailored for on-chain debt and credit, provides clients with higher yields, liquidation protection, and advanced predictive capabilities across the decentralized finance (DeFi) ecosystem, initially focusing on money markets.

Architect

Series A in 2024
Architect is a financial platform focused on enhancing trading access to global markets for digital assets. The company specializes in developing institutional-grade infrastructure that connects various trading venues, including both centralized and decentralized exchanges. By providing customizable solutions, Architect aims to streamline the trading process for users and facilitate participation in international markets for digital assets, futures, and options. Its innovative approach seeks to redefine how traders engage with the evolving landscape of digital finance.

Kinto

Seed Round in 2023
Kinto is the KYC'ed Layer 2 capable of supporting both modern financial institutions and decentralized protocols.

Kinto

Pre Seed Round in 2023
Kinto is the KYC'ed Layer 2 capable of supporting both modern financial institutions and decentralized protocols.

Shuttle Labs

Seed Round in 2023
Lore is developing the network and consumer tooling to onboard the next 1B users.

M^0 Labs

Venture Round in 2023
M^0 is money middleware for the digital age. It is a decentralized, on-chain protocol, as well as a corresponding set of off-chain standards and APIs, that allows holders of high-quality eligible collateral to participate in the issuance of a fungible cryptodollar. With M^0, any number of institutions around the world can tap on turnkey middleware to become their own cryptodollar issuer, upgrading their money tech stack to the digital age.

Architect

Seed Round in 2023
Architect is a financial platform focused on enhancing trading access to global markets for digital assets. The company specializes in developing institutional-grade infrastructure that connects various trading venues, including both centralized and decentralized exchanges. By providing customizable solutions, Architect aims to streamline the trading process for users and facilitate participation in international markets for digital assets, futures, and options. Its innovative approach seeks to redefine how traders engage with the evolving landscape of digital finance.

Nillion

Seed Round in 2022
Nillion is a computer and network security company that operates a decentralized public network based on a cryptographic primitive called Nil Message Compute (NMC). It develops a decentralized computing platform for secure processing and storage of high-value data, employing privacy technologies to enable confidential computations on masked data. The platform is designed to help healthcare and finance industries manage sensitive information while maintaining robust security standards and operational efficiency.

Prolific Machines

Series A in 2022
Prolific Machines is a biotech company founded in 2020 and based in San Francisco, California. The company specializes in developing advanced cell technologies aimed at transforming the production of cells for sustainable applications, particularly in the cultivated meat industry. By leveraging high-scale precision cell-differentiation techniques, Prolific Machines focuses on research and development in clean meat, cell therapies, and sustainable solutions for multi-planetary existence. Its innovations enable partners to adopt more sustainable practices, thereby enhancing human and planetary health while improving efficiency, quality, reproducibility, and sustainability in cell production.

Shuttle Labs

Venture Round in 2022
Lore is developing the network and consumer tooling to onboard the next 1B users.

CellX

Series A in 2022
CellX is pioneering the production of mushroom protein derived from morel mycelium fermentation, aiming to create innovative ingredient and product solutions suitable for savory snacks, protein powders, and meat alternatives. The company is actively involved in the commercialization of cultivated meat by licensing existing intellectual properties and developing advanced technology offerings, including suspension cell lines and serum-free media. These technologies have achieved impressive results, such as a cell density of 30 million cells per milliliter and a media cost of less than five dollars per liter, with successful testing conducted at a 2,000-liter scale. Additionally, CellX utilizes 3D bioprinting technology in its development of cell-cultivated meat products, reinforcing its commitment to sustainability and the provision of environmentally friendly and healthy animal protein alternatives.

UPSIDE Foods

Series C in 2022
UPSIDE Foods, formerly known as Memphis Meats, is a cultivated meat company founded in 2015 and headquartered in Berkeley, California. The company specializes in producing real meat, poultry, and seafood directly from animal cells, eliminating the need to raise and slaughter animals. This innovative approach significantly reduces the resource consumption associated with traditional meat production, requiring less water, land, and energy. UPSIDE Foods aims to offer consumers clean, humane, and sustainable meat products, such as beef meatballs, chicken, and duck, all grown in controlled environments. The company is led by Dr. Uma Valeti, who is committed to transforming the food industry with healthier and environmentally friendly alternatives to conventional meat.

Tessera Therapeutics

Series C in 2022
Tessera Therapeutics is an early-stage life sciences company focused on pioneering Gene Writing technology, which allows for the precise insertion of therapeutic messages into the human genome. This innovative approach aims to address diseases at their source by enabling both small and large genetic alterations. By building on recent advancements in gene therapy and gene editing, Tessera Therapeutics seeks to overcome existing limitations in these fields, enhancing their efficacy and reach. Founded by Flagship Pioneering, the company aspires to establish a new category in genetic medicine that can significantly improve patient outcomes and transform healthcare.

Minded

Seed Round in 2022
Minded is an online psychiatry practice focused on providing mental health care specifically for women. It operates a consumer telehealth platform that simplifies the process of obtaining and managing prescriptions for anxiety and depression. Through its platform, Minded enables patients to easily renew and refill their medications online, which are then delivered directly to their homes. This approach alleviates the challenges associated with scheduling appointments and managing medication supplies, ensuring that women can access the mental health support they need with greater convenience and efficiency.

Nucleus

Seed Round in 2021
Nucleus operates a biotechnology research platform focused on next-generation consumer genetic testing and analysis. The company allows users to upload their genetic information obtained from established providers and employs proprietary algorithms to calculate polygenic risk scores and assess disease risk based on genetic variants. Utilizing whole-genome sequencing, Nucleus delivers comprehensive genetic analysis, facilitating advancements in human health and medicine. The results are presented on a user-friendly platform, making complex genetic information accessible and understandable for users.

Cambrian Biopharma

Series C in 2021
Cambrian Biopharma is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life/overall quality of life as we age.

Gameto

Seed Round in 2020
Gameto is a biotechnology company focused on advancing female reproductive health through innovative therapies. Recognizing the significant lack of treatment options in this underserved area, Gameto employs cutting-edge scientific techniques to develop solutions that enhance the quality of life for women. The company utilizes cellular engineering to create a platform that produces engineered ovarian and endometrial cell lines capable of mimicking the functions of natural cells, including hormone production and response. This platform underpins a portfolio of cellular therapeutics aimed at addressing various female reproductive diseases. Gameto's first initiative, Fertilo, targets improvements in in vitro fertilization (IVF) and egg freezing processes, striving to make them shorter, safer, and more effective. Additionally, the company is developing Deovo, an organoid model of the female reproductive system, and Ameno, a cell-based therapy designed to mitigate health issues related to primary ovarian insufficiency and menopause. Through these efforts, Gameto aims to transform the landscape of female reproductive health care.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.